Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546388 · ClinicalTrials.gov registry record · NA
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
A NA study, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT02546388: Completed NA study, sponsored by Marcelo F. Di Carli, MD, FACC.
NCT02546388 is a NA study that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02546388, a NA study, has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Primary Outcome
To correlate localization and number of increased radiotracer foci between FDG-PET and DOTATATE studies.
Interventions
- DRUG Gallium-68 DOTATATE
- DRUG Indium-111 Pentreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-08 |
| Phase | NA |
What the finished NCT02546388 record still lists
NCT02546388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Gallium-68 DOTATATE is the first listed.
NCT02546388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02546388 about?
NCT02546388 is a clinical study titled "Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis". The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
What is the current status of trial NCT02546388?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02546388?
The interventions under investigation include: Gallium-68 DOTATATE (DRUG), Indium-111 Pentreotide (DRUG).
Who is sponsoring clinical trial NCT02546388?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02546388's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia